Development of drugs for celiac disease: Review of endpoints for Phase 2 and 3 trials

Gastroenterology Report

Volumn 3, Issue 2, 2015, Pages 91-102

  Gottlieb, Klaus ^a   Dawson, Jill ^a   Hussain, Fez ^a   Murray, Joseph A ^b  

^a IQVIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Celiac disease; Clinical trials; Endpoints

Indexed keywords

EID: 85037564445     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gov006     Document Type: Review

References (67)

1. Lammers K, Vasagar B and Fasano A. Definition of celiac disease and gluten sensitivity. In: SD Rampertab and GE Mullin (ed.). Celiac disease. New York: Springer, 2014, 13-25.
2. Husby S and Murray JA. Diagnosing coeliac disease and the potential for serological markers. Nat Rev Gastroenterol Hepatol 2014;11:655-63.
3. Green PHR, Stavropoulos SN, Panagi SG et al. Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol 2001;96:126-31.
4. Ludvigsson JF, Rubio-Tapia A, van Dyke CT et al. Increasing incidence of celiac disease in a North American population. Am J Gastroenterol 2013;108:818-24.
5. Fasano A, Berti I, Gerarduzzi T et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003;163:286-92.
6. Lohi S, Mustalahti K, Kaukinen K et al. Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther 2007;26: 1217-25.
7. Rubio-Tapia A, Ludvigsson JF, Brantner TL et al. The prevalence of celiac disease in the United States. Am J Gastroenterol 2012;107:1538-44.
8. Kaukinen K, Lindfors K and Mäki M. Advances in the treatment of coeliac disease: an immunopathogenic perspective. Nat Rev Gastroenterol Hepatol 2014;11:36-44.
9. Sapone A, Bai JC, Ciacci C et al. Spectrum of gluten-related dis-orders: consensus on new nomenclature and classification. BMC Med 2012;10:13.
10. FDA. Gluten and Food Labeling: FDA's Regulation of "Gluten-Free" Claims [Internet]. 2013 [cited 2014 Nov 23]. Available from: http://www.fda.gov/food/resourcesforyou/consumers/ucm367654.Htm
11. NPD Group. Food for thought: is gluten-free eating a trend worth noting? [Internet]. 2012 [cited 2014 Nov 23]. Available from: https://www.npd.com/perspectives/food-for-thought/gluten-free-2012.html
12. Rubio-Tapia A, Hill ID, Kelly CP et al. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013;108:656-76.
13. Coburn JA, Voort JLV, Lahr BD et al. Human leukocyte antigen genetics and clinical features of self-treated patients on a gluten-free diet. J Clin Gastroenterol 2013;47:828-33.
14. Ontiveros N, Tye-Din JA, Hardy MY et al. Ex-vivo whole blood secretion of interferon (IFN)-y and IFN-y-inducible protein-10 measured by enzyme-linked immunosorbent assay are as sensitive as IFN-y enzyme-linked immunospot for the detection of gluten-reactive T cells in human leucocyte antigen (HLA)-DQ2-5+-associated coeliac disease. Clin Exp Immunol 2014;175:305-15.
15. Husby S, Koletzko S, Korponay-Szabo I et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012;54:136-60.
16. Oxentenko AS and Murray JA. Celiac Disease: Ten Things That Every Gastroenterologist Should Know. Clin Gastroenterol Hepatol 2014 Jul 19. doi:10.1016/j.cgh.2014.07.024. [Epub ahead of print]
17. Hall NJ, Rubin GP and Charnock A. Intentional and inadvertent non-adherence in adult coeliac disease. A cross-sectional survey. Appetite 2013;68:56-62.
18. Hollon J, Cureton P, Martin M et al. Trace gluten contamination may play a role in mucosal and clinical recovery in a subgroup of diet-adherent non-responsive celiac disease patients. BMC Gastroenterol 2013;13:40.
19. Rubio-Tapia A, Rahim MW, See JA et al. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol 2010;105:1412-20.
20. Alvine Pharmaceuticals. Alvine Pharmaceuticals Doses First Patient in Phase 2B Trial for ALV003 in Celiac Disease [Internet]. 2013 [cited 2014 Nov 23]. Available from: http://www.alvinepharma.com/press-oct292013/
21. Lahdeaho ML, Kaukinen K, Laurila K et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology 2014;146:1649-58.
22. Tack GJ, Van de Water JM, Bruins MJetal. Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study. World J Gastroenterol 2013;19:5837-47.
23. Alba Therapeutics. Alba Therapeutics Announces Positive Results of Phase IIb Trial in Celiac Disease [Internet]. 2014 [cited 2014 Nov 23]. Available from: http://www.albathera-peutics.com/Portals/0/pdf/Alba%20Therapeutics%20FINAL% 20Press%20Release%20CLIN1001-012%20Larazotide%20Aceta te%20February%2011%202014.pdf
24. Business Monitor News & Views. Alba gets exclusive rights to CeD PRO; recruiting for Phase IIb trial [Internet]. 2012 [cited 2014 Nov 27]. Available from: http://www.businessmonitor. com/news-and-views/alba-gets-exclusive-rights-to-ced-pro-recruiting-for-phase-iib-trial
25. Wang C, Rasmussen H, Perrow W et al. 929b Larazotide Acetate, a First In-Class, Novel Tight Junction Regulator, Meets Primary Endpoint and Significantly Reduces Signs and Symptoms of Celiac Disease in Patients on a Gluten-Free Diet: Results of a Multicenter, Randomized, Placebo Controlled Trial. Gastroenterology 2014;146(Suppl 1):S159.
26. Leffler DA, Kelly CP, Abdallah HZ et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol 2012;107:1554-62.
27. Kelly CP, Green PHR, Murray JA et al. Larazotide acetate in pa-tients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther 2013;37:252-62.
28. Immusan T. ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease [Internet]. 2014. Available from: http://www.immusant.com/wp-content/up-loads/2011/06/ImmusanT-P1b-FINAL-9.4.121.pdf
29. Immusan T. ImmusanT's Immunotherapy for Celiac Disease, Nexvax2, Selected as One of Informa's Top 10 Autoimmune/Anti-Inflammatory Projects to Watch [Internet]. 2014 [cited 2014 Nov 23]. Available from: http://www.immusant.com/wp-content/uploads/2011/06/ImmusanT-TAP-Award-Press-Release-11.19.2014-FINAL.pdf
30. Bioline RX. Drugs in Development: BL-7010 [Internet]. 2012 [cited 2014 Nov 23]. Available from: http://www.biolinerx. com/default.asp?pageid14&itemid20
31. Clinicaltrials.gov. Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.[Internet]. 2014 [cited 2014 Nov 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01990885?termBL-7010&rank1
32. Avaxia Biologics. Avaxia Biologics is Awarded Patent for its Proprietary Orally Active Antibody for Celiac Disease [Internet]. 2011 [cited 2014 Nov 23]. Available from: http://www.avaxiabiologics.com/docs/rev-11-12-13-Celiac-Disease-Treatment-Patent.pdf
33. Acto GeniX. Clinical Stage Drug Development Platform Developing Therapeutics for GI, Mucosal and Immunological Diseases [Internet]. 2014 Sep [cited 2014 Nov 23]. Available from: http://www.actogenix.com/wp-content/uploads/Actogenix-Corporate-September-2014-Non-Confidential1. pdf
34. Huibregtse IL, Marietta EV, Rashtak S et al. Induction of anti-gen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice. J Immunol 2009;183:2390-6.
35. ChemoCentryx. CCR9 Program [Internet]. 2014 [cited 2014 Nov 23]. Available from: http://www.chemocentryx.com/product/CCR9.html
36. FDA. Guidance for Industry and Review Staff Target Product Profile-A Strategic Development Process Tool-Draft [Internet]. 2007 [cited 2014 Nov 23]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregula-toryinformation/guidances/ucm080593.pdf
37. Fleming TR and Powers JH. Biomarkers and surrogate end-points in clinical trials. Stat Med 2012;31:2973-84.
38. Fiorentino R, Liu G, Pariser AR et al. Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseases. J Allergy Clin Immunol 2012;130:613-16.
39. Dorn SD, Hernandez L, Minaya MT et al. The development and validation of a new coeliac disease quality of life survey (CD-QOL). Aliment Pharmacol Ther 2010;31:666-75.
40. Leffler DA, Dennis M, Edwards George J et al. A validated dis-ease-specific symptom index for adults with celiac disease. Clin Gastroenterol Hepatol 2009;7:1328-34.e3
41. Hauser W, Gold J, Stallmach A et al. Development and validation of the Celiac Disease questionnaire (CDQ), a disease-specific health-related quality of life measure for adult patients with celiac disease. J Clin Gastroenterol 2007;41:157-66.
42. Revicki DA, Wood M, Wiklund I et al. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res 1997;7:75-83.
43. Taavela J, Kurppa K, Collin P et al. Degree of damage to the small bowel and serum antibody titers correlate with clinical presentation of patients with celiac disease. Clin Gastroenterol Hepatol 2013;11:166-71.e1
44. FDA. Drug Development Tools (DDT) Qualification Programs [Internet]. 2014 [cited 2014 Nov 27]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDev elopmentToolsQualificationProgram/
45. Adelman D, Leffler D, Lebwohl B et al. Celiac Disease Symptom Frequency and Severity Using A Disease-Specific Patient-Reported Outcome Diary: Observations From A Psychometric Validation Study in 202 Patients. Am J Gastroenterol 2012;107:S603.
46. Husby S and Murray JA. New aspects of the diagnosis of celiac disease in children, adolescents, and adults. Mayo Clin Proc 2013;88:540-3.
47. Marsh MN and Crowe PT. Morphology of the mucosal lesion in gluten sensitivity. Baillieres Clin Gastroenterol 1995;9:273-93.
48. Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 1992;102:330-54.
49. Oberhuber G, Granditsch G and Vogelsang H. The histopa-thology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999;11: 1185-94.
50. Corazza G and Villanacci V. Coeliac disease. J Clin Pathol 2005; 58:573-4.
51. Ensari A. Gluten-sensitive enteropathy (celiac disease): con-troversies in diagnosis and classification. Arch Pathol Lab Med 2010;134:826-36.
52. Taavela J, Koskinen O, Huhtala H et al. Validation of morpho-metric analyses of small-intestinal biopsy readouts in celiac disease. PLoS ONE 2013;8:e76163.
53. Järvinen TT, Kaukinen K, Laurila K et al. Intraepithelial lym-phocytes in celiac disease. Am J Gastroenterol 2003;98:1332-7.
54. Corazza GR, Villanacci V, Zambelli C et al. Comparison of the inter-observer reproducibility with different histologic criteria used in celiac disease. Clin Gastroenterol Hepatol 2007;5:838-43.
55. Lebwohl B, Kapel RC, Neugut AI et al. Adherence to biopsy guidelines increases celiac disease diagnosis. Gastrointest Endosc 2011;74:103-9.
56. Evans KE, Aziz I, Cross SS et al. A prospective study of duodenal bulb biopsy in newly diagnosed and established adult ce-liac disease. Am J Gastroenterol 2011;106:1837-42.
57. Leffler DA, Schuppan D, Pallav K et al. Kinetics of the histo-logic, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut 2013;62:996-1004.
58. Gopalakrishnan S, Durai M, Kitchens K et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides 2012;35:86-94.
59. Paterson B, Lammers K, Arrieta M et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007;26:757-66.
60. Jauregi-Miguel A, Fernandez-Jimenez N, Irastorza I et al. Alteration of tight junction gene expression in celiac disease. J Pediatr Gastroenterol 2014;58:762-7.
61. World Health Organization. International Clinical Trials Registry Platform-Search Portal [Internet]. 2014 [cited 2014 Dec 4]. Available from: http://apps.who.int/trialsearch/
62. Mahadev S, Simpson S, Lebwohl B et al. Is dietitian use associated with celiac disease outcomes? Nutrients 2013;5:1585-94.
63. Vives-Pi M, Takasawa S, Pujol-Autonell I et al. Biomarkers for diagnosis and monitoring of celiac disease. J Clin Gastroenterol 2013;47:308-13.
64. McMillan S, Dickey W, Douglas J et al. Transthyretin values correlate with mucosal recovery in patients with coeliac disease taking a gluten-free diet. J Clin Pathol 2001;54:783-6.
65. Neurath MF and Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012;61:1619-35.
66. Lebwohl B, Granath F, Ekbom A et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann Intern Med 2013;159:169-75.
67. Dellon ES, Gonsalves N, Hirano I et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol 2013;108:679-92.